Committee Clear On Need For Fracture Data For New Calcitonin Drugs
Executive Summary
A March 5 FDA advisory panel gave a mixed assessment of whether nasal spray formulations of the products should remain on the market for postmenopausal osteoporosis, but overwhelmingly agreed that new versions should meet a higher efficacy standard.
You may also be interested in...
US FDA Taps Pfizer Executive For CDER Deputy Director Slot
Patrizia Cavazzoni, Janet Woodcock's new #2, has a background similar to Richard Moscicki, CDER's previous deputy director for operations.
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.
Track-And-Trace: With Deadline a Year Away, Some Lessons from Early Adopters
EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.